NOTCH2 and pancreatic adenocarcinoma: ROC analysis demonstrated that NOTCH2 had strong diagnostic performance for pancreatic cancer, with an AUC of 0.829 in the TCGA-PAAD cohort and 0.823 in the GSE15471 cohort (Figure 5B).